The best TV for Switch 2 has an $800 discount today
Why you should buy the 55-inch Samsung S90D OLED 4K TV
The Samsung S90D is an amazing OLED TV that was recommended as the best TV for the Nintendo Switch 2 by Digital Trends' A/V pros. Its QD-OLED technology delivers a wide color gamut, intense brightness, and inky black levels, which are perfect to enjoy the graphics and gameplay of Nintendo Switch 2 games when the console is hooked up to the TV for docked mode. The 55-inch screen is also a nice size for video games, though you may want to check our guide on what size TV to buy to make sure you have enough space for it.
When you're taking a break from playing video games, the Samsung S90D OLED 4K TV is also a fantastic display for watching streaming shows. It's powered by Samsung's Tizen OS, which is compatible with all of the popular streaming services, and all the content with lower resolution that you'll watch will be upgraded with 4K AI Upscaling.
In one of the most attractive Samsung TV deals that you can shop right now, the 55-inch Samsung S90D OLED 4K TV is $800 off, which slashes its price from $2,000 to just $1,200. That's a steal when you consider the capabilities of this OLED TV, especially if you'll be using it for playing video games with your Nintendo Switch 2 or any other console. You need to hurry though, as tomorrow may already be too late to take advantage of this discount for the 55-inch Samsung S90D OLED 4K TV.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
10 minutes ago
- Associated Press
Aeries Technology Forms Independent Advisory Board to Accelerate Strategic Growth and Market Impact
New York, New York--(Newsfile Corp. - July 7, 2025) - Aeries Technology (NASDAQ: AERT), a global leader in AI-powered value creation, business transformation, and Global Capability Center (GCC) delivery for private-equity (PE) portfolio companies, today announced the formation of its Independent Strategic Advisory Board, reinforcing the company's commitment to growth, innovation, and long-term client success. Designed to be engaged and impact-driven, the Advisory Board will work in close partnership with Aeries' management team to advance strategic priorities, identify and pursue new commercial opportunities, and ensure the company stays aligned with the evolving needs of its clients. By incorporating the 'voice of the customer' into strategic discussions and leveraging deep industry expertise and relationship networks, the Advisory Board will serve as a source of insights and catalyst for execution. Ramesh Venkataraman will chair the Advisory Board. A seasoned private-equity investor and former McKinsey partner, Ramesh is the Founder and Managing Partner at Avest and has held senior leadership roles at Bridgepoint and McKinsey, advising global clients across financial services, infrastructure, and technology. 'We're assembling a group of experienced leaders with a clear mandate: to add real value,' said Ramesh. 'This Board is built to inform strategic choices, provide insights into clients and what matters most to them, and help Aeries shape its offerings.' Ajay Khare, CEO of Aeries Technology, added, 'This Advisory Board brings both perspective and experience. With Ramesh's leadership and the collective strength of the group, we're enhancing our ability to execute with focus and agility.' As Aeries continues to scale, the Advisory Board will play a key role in helping the company navigate an increasingly complex landscape — supporting strategy with insight, experience, and action. About Aeries Technology Aeries Technology (NASDAQ: AERT) is a global leader in AI-enabled value creation, business transformation, and Global Capability Center (GCC) delivery for private-equity (PE) portfolio companies, supporting scalable, technology-driven execution. Founded in 2012, its commitment to workforce development has earned it the Great Place to Work Certification for two consecutive years. Media Contact [email protected] To view the source version of this press release, please visit
Associated Press
10 minutes ago
- Associated Press
Alfa Cytology Announces Holistic Approach to RDC Development Services Supported by In Vivo Studies in Radiopharmaceuticals
Illustration of TAT Alfa Cytology has announced RDC development services supported by In Vivo studies in radiopharmaceuticals. Alfa Cytology, a leading-edge biotech company engaged in cancer research, has released its services on robust RDC (Radionuclide Drug Conjugate) development technical support for radiopharmaceuticals. The services are specifically designed to transform the radiopharmaceutical industry, enhancing quality and precision for disease diagnosis and therapy. The oncology and diagnostic imaging fields are rapidly expanding, with an increasing need for transformative approaches to medical research and treatment. As current methods in disease diagnosis and treatment often lack the specificity, sensitivity, and customization demanded by the cutting edge of diagnostic medicine and theranostics, Alfa Cytology has developed the platform to meet the individualized needs of its clients. This takes a highly individualized approach, accounting for the specific biochemical and kinetic characteristics of the large variety of radiotracers and therapeutics in use. Alfa Cytology's expert services can be leveraged for the custom synthesis, optimization, and quality control of radiopharmaceuticals, to a standard of safety and efficacy unequaled by other service providers. An essential component is in vivo studies in radiopharmaceuticals. These studies, which give critical insights into the in vivo interactions and pharmacodynamics of radiopharmaceuticals, form the backbone of a rigorous approach to therapeutic radiopharmaceutical development. The research is supported by an extensive imaging and analytical infrastructure, enabling researchers to better understand the biodistribution, safety, pharmacokinetics, and overall therapeutic potential of next-generation radiopharmaceutical agents. The in vivo research option is a critical tool in efforts to develop more targeted and individualized radiopharmaceutical therapeutics and diagnostics. Alfa Cytology offers a wide range of technical support options and expert services for research teams, including custom synthesis of radiotracers, radionuclide production, labeling methodologies, and advanced analytical support to maximize radiochemical purity, as well as radioanalytical support and method development. Alfa Cytology continues to expand its service offerings and is continuously updating its highly experienced technical teams to meet the increasingly complex demands of the research community and to continue to be a resource for innovation and development in diagnostic imaging and cancer therapy. Alfa Cytology provides a fully integrated infrastructure to leverage RDC services and take advantage of cutting-edge in vivo research, connecting the laboratory to the real world. About Alfa Cytology Alfa Cytology, headquartered in New York, is a CRO company, offering state of the art solutions in radiopharmaceutical R&D. Alfa Cytology's team of industry veterans have assembled a set of broad integrated skills in molecular imaging, radiochemistry, and regulatory sciences, which allow them to provide next-generation services across the broad range of research needs within the community. For more information on the newest tools and solutions in radiopharmaceuticals, visit our service pages to learn how Alfa Cytology is redefining the future of cancer research and nuclear medicine. Media Contact Company Name: Alfa Cytology Contact Person: Thassia C. Email: Send Email Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Alfa Cytology Announces Holistic Approach to RDC Development Services Supported by In Vivo Studies in Radiopharmaceuticals
Associated Press
10 minutes ago
- Associated Press
Klazik Releases New Single 'Ovation' — Gaining Early Chart Momentum Ahead of Official Launch
Ovation makes waves before its official release, earning over 4,000 internet radio spins and debuting at #40 on the DRT Independent Airplay Chart. 'Midwestern rapper Klazik's 'Ovation' is a hard-hitting new release that blends hip hop elements with an undeniable club vibe, making it the perfect soundtrack for a night out on the town.'— Steven Azami WEST DES MOINES, IA, UNITED STATES, July 7, 2025 / / -- While the nation celebrated Independence Day with fireworks, the Voice of Adult Contemporary Hip Hop, Klazik, celebrated a major win of his own. His brand-new single 'Ovation' officially dropped—but it's already making serious waves across the airwaves. In a strategic move that reflects both his grassroots ethos and growing industry savvy, Klazik released 'Ovation' exclusively to internet radio ahead of the official launch. The response? Explosive. The single has already garnered over 4,000 spins and broken into the Top 40 on the DRT Independent Airplay Chart, landing at #40 even before it became publicly available. A follow-up to his critically praised release 'Get to You', 'Ovation' is a grown, confident, and hypnotic blend of modern hip hop and timeless charisma. With flirtatious bars, ghostly ad-libs, and a beat built for both the club and the culture, 'Ovation' showcases the signature style that has made Klazik a standout in today's rap landscape. 'Throw this song on at any point on your night out' Klazik shares. 'You cant go wrong.' ____________________________________________________________________________________________________________________________________________________________ Known for pioneering the Adult Contemporary Hip Hop genre, Klazik continues to carve a lane that honors the craft while pushing it forward. His music speaks to real experiences, elevated perspectives, and the kind of polished storytelling that resonates far beyond trends. 'Ovation' is now available on major streaming streaming platforms and Klazik's Official YouTube Page. Official Press Team Adult Contemporary Hip Hop email us here Visit us on social media: YouTube Instagram TikTok Facebook Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
